Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 6, 2001, Pages 1771-1779

  Schöler, Nadja ^a   Krause, Karsten ^b   Kayser, Oliver ^b   Müller, Rainer H ^b   Borner, Klaus ^a   Hahn, Helmut ^a   Liesenfeld, Oliver ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; PYRIMETHAMINE SULFADIAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG EFFICACY; ENCEPHALITIS; FEMALE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE DEFICIENCY; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INJECTIONS, INTRAVENOUS; MACROPHAGES, PERITONEAL; MALE; MICE; NAPHTHOQUINONES; SULFADIAZINE; SUSPENSIONS; TISSUE DISTRIBUTION; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

EID: 0343831483     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.6.1771-1779.2001     Document Type: Article

References (48)

1. Alyautdin, R., D. Gothier, V. Petrov, D. Kharkevich, and J. Kreuter. 1995. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41:44-48.
2. Araujo, F. G., J. Huskinson, and J. S. Remington. 1991. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 35:293-299.
3. Araujo, F. G., J. Huskinson-Mark, W. E. Gutteridge, and J. S. Remington. 1992. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob. Agents Chemother. 36:326-330.
4. Araujo, F. G., A. A. Khan, and J. S. Remington. 1996. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob. Agents Chemother. 40:1335-1337.
5. Araujo, F. G., A. A. Khan, T. L. Slifer, A. Bryskier, and J. S. Remington. 1997. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob. Agents Chemother. 41:2137-2140.
6. Araujo, F. G., T. Lin, and J. S. Remington. 1992. Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice. Eur. J. Clin. Microbiol. Infect. Dis. 11:71-73.
7. Araujo, F. G., P. Prokocimer, T. Lin, and J. S. Remington. 1992. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob. Agents Chemother. 36:2454-2457.
8. Araujo, F. G., R. M. Shepard, and J. S. Remington. 1991. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur. J. Clin. Microbiol. Infect. Dis. 10:519-524.
9. Araujo, F. G., T. Slifer, and J. S. Remington. 1994. Rifabutin is active in murine models of toxoplasmosis. Antimicrob. Agents Chemother. 38:570-575.
10. Blunk, T., D. F. Hochstrasser, J. C. Sanchez, B. W. Müller, and R. H. Müller. 1993. Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14:1382-1387.
11. Cohn, J., A. McMeeking, and W. Cohen. 1989. Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am. J Med. 86:521-527.
12. Conley, F. K., K. A. Jenkins, and J. Remington. 1981. Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum. Pathol. 12:690-698.
13. De Angelis, D. V., J. D. Long, L. L. Kanics, and J. L. Woolley. 1994. High-performance liquid chromatographic assay for the measurement of atovaquone in plasma. J. Chromatogr. 652:211-219.
14. Denkers, E. Y., and R. T. Gazzinelli. 1998. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 11:569-588.
15. Ferguson, D. J., J. Huskinson-Mark, F. G. Araujo, and J. S. Remington. 1994. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. Int. J. Exp. Pathol. 75:111-116.
16. Grau, J. M., O. Kayser, and R. H. Müller. 2000. Nanosuspensions of poorly soluble drugs - reproducibility of small scale production. Int. J. Pharm. 196: 155-159.
17. Gutteridge, W. E. 1991. 566C80, an antimalarial hydroxynaphthoquinone with broad spectrum experimental activity against opportunistic parasitic infections of AIDS patients. J. Protozool. 38:141-143.
18. Handler, M., V. Ho, and M. Whelan. 1983. Intracerebral toxoplasmosis in patients with acquired immune deficiency syndrome. J. Neurosurg. 59:994-1001.
19. Hannan, S. I., G. A. Ridout, and A. E. Jones. 1996. Determination of the potent antiprotozoal compound atovaquone in plasma using liquid-liquid extraction followed by reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 678:297-302.
20. Hansson, A. G., S. Mitchell, P. Jatlow, and P. M. Rainey. 1996. Rapid high-performance liquid chromatographic assay for atovaquone. J. Chromatogr. B 675:180-182.
21. Holschke, T., J. Löhler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K. P. Knobeloch, L. Gabriele, J. F. Waring, M. F. Bachmann, R. M. Zinkernagel, H. C. Morse, K. Ozato, and I. Horak. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307-317.
22. Hughes, W., G. Leoung, F. Kramer, S. A. Bozzette, S. Safrin, and P. Frame. 1993. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N. Engl. J. Med. 328:1521-1527.
23. Hughes, W. T., W. Kennedy, J. L. Shenep, P. M. Flynn, S. V. Hetherton, and G. Fullen. 1991. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J. Infect. Dis. 163:843-848.
24. Huskinson-Mark, J., F. G. Araujo, and J. S. Remington. 1991. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J. Infect. Dis. 164:170-177.
25. Israelski, D. M., and J. S. Remington. 1992. AIDS-associated toxoplasmosis, p. 319-345. In M. A. Sande and P. A. Volberding (ed.), The medical management of AIDS, 3rd ed. W. B. Saunders, Philadelphia, Pa.
26. Israelski, D. M., and J. S. Remington. 1993. Toxoplasmosis in the non-AIDS immunocompromised host. Curr. Clin. Top. Infect. Dis. 13:322-356.
27. Katlama, C., S. De Wit, E. O'Doherty, M. Van Glabeke, and N. Clumeck. 1996. Pyrimethamine-clindamycin versus pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis. 22:268-275.
28. Kaufman, H. E., and P. H. Geisler. 1960. The hematologic toxicity of pyrimethamine (Daraprim) in man. Arch. Ophthalmol. 64:140-146.
29. Khan, A. A., F. G. Araujo, J. C. Craft, and J. S. Remington. 2000. Ketolide ABT-773 is active against Toxoplasma gondii. J. Antimicrob. Chemother. 46:489-492.
30. Kreuter, J., V. E. Petrov, D. A. Kharkevich, and R. N. Alyautdin. 1997. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release 49:81-87.
31. Leport, C., F. Raffi, and S. Matheron. 1988. Treatment of central nervous system toxoplasmosis with pyrimethamine-sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome: efficacy of long-term continuous therapy. Am. J. Med. 84:94-100.
32. Liesenfeld, O., S. Y. Wong, and J. S. Remington. 1998. Toxoplasma in setting of AIDS, p. 225-259. In T. C. Merigan, Jr., J. G. Bartlett, and D. Bolognesi (ed.), Textbook of AIDS medicine, 2nd ed. Williams & Wilkins, Baltimore, Md.
33. Luft, B. J., and J. S. Remington. 1988. AIDS commentary: toxoplasmic encephalitis. J. Infect. Dis. 157:1-6.
34. Luft, B. J., and J. S. Remington. 1992. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 15:211-222.
35. Mosmann, T. R. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods 65:55-63.
36. Müller, R. H., S. Benita, and B. H. L. Böhm. 1998. Emulsions and nanosuspensions for the formulation of poorly soluble drugs, medpharm Verlag GmbH, Stuttgart, Germany.
37. Müller, R. H., and K. Peters. 1998. Nanosuspensions for the formulation of poorly soluble drugs. 1. Preparation by size reducing technique. Int. J. Pharm. 160:229-237.
38. 37a. Müller, R. H., M. Lück, and J. Kreuter. 1997. German patent 197 45 950.1.
39. Pfefferkorn, E. R., S. E. Borotz, and R. F. Nothnagel. 1993. Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate. J. Parasitol. 79:559-564.
40. Porter, S. B., and M. A. Sande. 1992. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N. Engl. J. Med. 327: 1643-1648.
41. Rolan, P. E., A. J. Mercer, B. C. Weatherly, T. Holdich, H. Meire, and R. W. Peck. 1994. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br. J. Clin. Pharmacol. 37:13-20.
42. Romand, S., M. Pudney, and F. Derouin. 1993. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob. Agents Chemother. 37:2371-2378.
43. Rousseau, F., S. Pueyo, and P. Morlat. 1997. Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. Clin. Infect. Dis. 24:396-402.
44. Scharton-Kersten, T., C. Contursi, A. Masumi, A. Sher, and K. Ozato. 1997. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J. Exp. Med. 186:1523-1534.
45. Schöler, N., E. Zimmermann, U. Katzfey, H. Hahn, R. H. Müller, and O. Liesenfeld. 2000. Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. J. Microencapsul. 17:639-650.
46. Sordet, F., Y. Aumjaud, H. Fessi, and F. Derouin. 1998. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite 5:223-229.
47. Spencer, C. M., and K. L. Goa. 1995. Atovaquone: a review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs 50:176-196.
48. Suzuki, Y., H. Kang, S. Parmley, S. Lim, and D. Park. 2000. Induction of tumor necrosis factor-α and inducible nitric oxide synthase fails to prevent toxoplasmic encephalitis in the absence of interferon-γ in genetically resistant BALB/c mice. Microbes Infect. 2:455-462.